You are pooh-poohing the FDA's (public health) concern over adherence. Assuming that you're correct, why would some people motivated to get a surgical implant that has no significant adverse side effects, then not use it for the defined period of the trial? Assuming that the trial participants are representative of the population that will get these implants post-trial, should non-adherents be ignored? Adherence to a therapeutic is an important aspect to consider. From a public health standpoint, the efficacy of a therapeutic in practice is more important that what it is in theory. For example, the contraceptive efficacy of condoms in theory is quite better than it is in practice. Which do you think a public health worker should give more weight?
No one has posted a cogent counter-argument to oozhe's assertions, just stupid, tired putdowns like yours. If that's all you've got, then maybe oozhe is right about this, regardless whether it's a basher.
"If" is the key word, and applicable to thousands of drug candidates out there. 2125 is too far off to be counting its golden eggs now.
8400 ain't gonna be standard of care for millions of cancer patients. And it's very early to be speculating about 2125 being a cancer panacea.
Buy at pre-PDUFA trough ($6.30 is close enough) for run-up to PDUFA date (Oct. 23). This is a golden opportunity. Even if there is a general market correction beforehand, it likely won't be too bad or lasting, and BDSI shouldn't drop much more. Send me 10% of your profit for the tip.
Apparently, you can't read. Welcome to ignore, loser.
"3. The shares of common stock were sold under a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs."
Big deal. You wanna give me 20K shares and post it as positive news? Never mind. Both the stupid bashers and pumpers on this board are a waste of space, so welcome to my ignore list, all of you.
How is it relevant to anything that this director, along with others, got stock grants that vested on that date? Do you somehow think that that's positive for the stock or company? I'd love to hear your explanation.
Company has a year to get stock above $1 to satisfy Nasdaq before RS would be necessary. Why do you parrot RS?
It appears that the insufferable blowhard, realstats/jgeorge, has switched sides after bashing for over a month. When is that reverse split due again, ya dumbkopf?
realstats is also jgeorge, who has made a career out of pumping IGXT (and his ego) and lately (since early July?) bashing ETRM. An insufferable blowhard with probably more Yahoo IDs. Reminds me of Donald Trump.
What's ridiculous is an investor comparing stock prices of different companies as if it's equivalent to comparing their market capitalizations. Really ridiculous.